Susquehanna Portfolio Strategies LLC Sells 3,700 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Susquehanna Portfolio Strategies LLC lessened its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 20.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,476 shares of the company’s stock after selling 3,700 shares during the period. Susquehanna Portfolio Strategies LLC’s holdings in Kymera Therapeutics were worth $432,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in shares of Kymera Therapeutics by 18.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after acquiring an additional 996,300 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Kymera Therapeutics by 19.2% in the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after purchasing an additional 769,486 shares during the last quarter. Norges Bank bought a new position in Kymera Therapeutics in the 4th quarter worth about $12,834,000. Artal Group S.A. grew its position in Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after purchasing an additional 496,400 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Kymera Therapeutics by 229.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock valued at $17,177,000 after purchasing an additional 469,947 shares in the last quarter.

Kymera Therapeutics Trading Down 1.6 %

KYMR opened at $48.69 on Friday. The company’s 50 day moving average is $45.79 and its 200 day moving average is $39.35. The company has a market cap of $2.99 billion, a price-to-earnings ratio of -19.40 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12-month low of $9.60 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.10. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. During the same quarter in the previous year, the firm posted ($0.67) EPS. The company’s revenue for the quarter was up 55.2% compared to the same quarter last year. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KYMR. HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of Kymera Therapeutics in a report on Monday, June 17th. Oppenheimer lifted their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Wells Fargo & Company lifted their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Finally, B. Riley upped their target price on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.00.

Insider Transactions at Kymera Therapeutics

In related news, insider Jared Gollob sold 23,145 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total value of $1,060,272.45. Following the completion of the sale, the insider now directly owns 95,470 shares of the company’s stock, valued at approximately $4,373,480.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Kymera Therapeutics news, insider Jared Gollob sold 23,145 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total value of $1,060,272.45. Following the completion of the sale, the insider now owns 95,470 shares in the company, valued at approximately $4,373,480.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the sale, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The disclosure for this sale can be found here. Insiders have sold 495,605 shares of company stock valued at $19,303,364 over the last quarter. 15.82% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.